Press Releases Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:32 2025-12-16 EST			5-day change	1st Jan Change
98.27 ^USD	-1.98%		+1.42%	-1.22%

12-16	Sector Update: Health Care Stocks Retreat Late Afternoon	MT
12-16	Sector Update: Health Care	MT

Press Releases

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)	12-12	BU
Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030	12-12	AQ
Saskatchewan Adds CAPVAXIVE® to Publicly Funded Adult Immunization Program	12-08	AQ
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)	12-04	BU
Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025	12-01	BU
Merck to Participate in the Citi 2025 Global Healthcare Conference	11-26	BU
Merck to Participate in the 8th Annual Evercore ISI HealthCONx Conference	11-26	BU
Merck Data to be Presented at ASH 2025 Annual Meeting Showcase Continued Advancements in Hematology Pipeline and Novel Therapeutic Approaches	11-24	BU
Merck Recommends Rejection of Tutanota’s “Mini-Tender” Offer	11-21	BU
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), as Perioperative Treatment for Adults with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	11-21	BU
Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)	11-20	AQ
Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) in Treatment-Naïve Adults with HIV-1 Infection	11-19	BU
European Commission Approves Subcutaneous Administration of KEYTRUDA® (pembrolizumab) for All Adult Indications Approved in the European Union	11-19	BU
Merck Announces First-Quarter 2026 Dividend	11-18	BU
Merck Commemorates 5 Billion Mectizan Treatments Donated Over 38 Years	11-18	AQ
Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to Heart Failure With Preserved Ejection Fraction (HFpEF)	11-18	BU
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent	11-17	AQ
Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent	11-14	BU
Merck to Participate in the Jefferies Global Healthcare Conference in London	11-13	BU
Merck : Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial	11-09	PU
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial	11-09	BU
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial	11-08	BU
Quebec Expands Public Funding for CAPVAXIVE®	11-05	AQ
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)	11-04	BU
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody	11-04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Merck to Buy Verona Pharma for About $10B

July 09, 2025 at 12:30 pm